PMID- 29171468
OWN - NLM
STAT- MEDLINE
DCOM- 20180327
LR  - 20221207
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 89
IP  - 10
DP  - 2017
TI  - [Glycemic variability and oxidative stress in patients with type 2 diabetes 
      mellitus during combined glucose-lowering therapy].
PG  - 36-39
LID - 10.17116/terarkh2017891036-39 [doi]
AB  - AIM: To evaluate the impact of intensified glucose-lowering therapy on 
      carbohydrate metabolic indicator, such as glycated hemoglobin, fasting blood 
      glucose level (BGL) (FBGL), postprandial BGL (PBGL), and glycemic variability 
      (GV) in patients with type 2 diabetes mellitus (T2DM) during metformin 
      monotherapy before and 3 months after therapy intensification. SUBJECTS AND 
      METHODS: The investigation enrolled 51 patients with T2DM treated with metformin 
      1000 mg twice daily, who failed to achieve satisfactory glycemic control. During 
      randomization, the treatment was intensified by addition of sitagliptin 100 
      mg/day in Group 1 (n=25) or gliclazide MB 60 mg/day in Group 2 (n=26). Before and 
      3 months after the treatment, carbohydrate metabolic indicators were 
      investigated, 24-hour BGL monitoring (continuous glucose monitoring system (GMS)) 
      was performed, and the body's antioxidant status was examined by determining the 
      total antioxidant capacity of blood plasma (overall sound pressure levels 
      (OASPL)). RESULTS: During 3-month treatment, Group 1 had a significantly reduced 
      FBGL compared to that before the therapy; in Group 2 this index did not change 
      significantly. Both study groups showed a significant decrease in PBGL and 
      glycated hemoglobin (HbA1c). The mean amplitude of glycemic excursion (MAGE) was 
      significantly decreased in the sitagliptin intensification group. In both groups, 
      the standard deviation (SD) reduced significantly by 26% in Group 1 and by 38% in 
      Group 2. Both groups also displayed a significant increase in blood OASPL 
      (p<0.05). CONCLUSION: The addition of sitagliptin significantly affected the 
      change in the indicators of both the standard carbohydrate metabolism (FBGL, 
      PBGL, and HbA1c) and GV (MAGE, SD), whereas that of gliclazide MV altered some 
      studied parameters. OASPL significantly increased in both groups.
FAU - Butaeva, S G
AU  - Butaeva SG
AD  - Russian Medical Academy of Continuing Professional Education, Ministry of Health 
      of Russia, Moscow, Russia.
FAU - Ametov, A S
AU  - Ametov AS
AD  - Russian Medical Academy of Continuing Professional Education, Ministry of Health 
      of Russia, Moscow, Russia.
FAU - Bugrov, A V
AU  - Bugrov AV
AD  - Russian Medical Academy of Continuing Professional Education, Ministry of Health 
      of Russia, Moscow, Russia.
FAU - Dolgov, V V
AU  - Dolgov VV
AD  - Russian Medical Academy of Continuing Professional Education, Ministry of Health 
      of Russia, Moscow, Russia.
LA  - rus
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Variabel'nost' urovnia gliukozy v krovi i okislitel'nyi stress u bol'nykh 
      sakharnym diabetom 2-go tipa na fone kombinirovannoi sakharosnizhaiushchei 
      terapii.
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - G4PX8C4HKV (Gliclazide)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Analysis of Variance
MH  - *Blood Glucose/analysis/metabolism
MH  - *Diabetes Mellitus, Type 2/diagnosis/drug therapy/metabolism
MH  - Drug Monitoring/methods
MH  - Drug Therapy, Combination/methods
MH  - Female
MH  - Gliclazide/*administration & dosage
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Oxidative Stress/*drug effects
MH  - Sitagliptin Phosphate/*administration & dosage
MH  - Treatment Outcome
OTO - NOTNLM
OT  - glycemic variability
OT  - oxidative stress
OT  - type 2 diabetes mellitus
EDAT- 2017/11/25 06:00
MHDA- 2018/03/28 06:00
CRDT- 2017/11/25 06:00
PHST- 2017/11/25 06:00 [entrez]
PHST- 2017/11/25 06:00 [pubmed]
PHST- 2018/03/28 06:00 [medline]
AID - 10.17116/terarkh2017891036-39 [doi]
PST - ppublish
SO  - Ter Arkh. 2017;89(10):36-39. doi: 10.17116/terarkh2017891036-39.